Indefinite Delivery Contract SPE2DU25D9217

This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,999,999, is part of the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) and aims to establish Prime Vendor Contracts to provide worldwide pharmaceutical support to various DoD customers, including the Defense Health Agency, Department of Defense, United States Coast Guard, and US Naval Fleet.

The contract covers a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications. DMS Pharmaceutical Group will be responsible for furnishing these pharmaceutical products in accordance with the specified ordering, packaging, shipping, receiving, and unique requirements. The contract has a 30-month base period with three 30-month option periods, for a total potential performance period through December 2036. This is a firm-fixed price, requirements-type contract awarded on a lowest price technically acceptable (LPTA) basis, with the potential use of reverse auctions to determine the final distribution fees.